Nobel Lecture: Emmanuelle Charpentier, Nobel Prize in Chemistry 2020

Scientists won the Nobel Prize
12 followers
2 Video Views·Dec 23, 2025
Emmanuelle Charpentier was born in 1968 in Chevisy-sur-Orge in France. She obtained her PhD
in 1995 from Institut Pasteur in Paris and for part of her career she worked at Umeå University
in Sweden. She is now director of the Max Planck unit for the science of pathogens in Berlin,
Germany. Emmanuelle Charpentier, I now welcome you onto the stage. We are very much looking
forward to hearing your lecture. Dear ladies and gentlemen, I am delighted to welcome you to my
Nobel lecture. It is the greatest honor to be awarded together with Jennifer Doudna
the Nobel Prize in Chemistry for the year 2020 for the development of a method for genome editing.
I would like to warmly thank the members of the Royal Swedish Academy of Sciences,
the members of the Nobel Committee and all scientists who have supported our nomination.
I wish I will be able to give the lecture live. Unfortunately, it is a recorded lecture,
but I hope you will enjoy the recording. I would like to start with explaining you
the CRISPR-Cas9 technology that is this novel method for genome editing.
Over the years, all biologists have been extremely interested in always using
genetics to understand the functions of genes. We are always in need of precise genetics
that allows us to recognize site-specific DNA of genomes of cells and organisms,
and allows us to modify genes and their expression. This is what the CRISPR-Cas9 technology does.
The particularity of this technology is that it is a sophisticated technology, yet
very simple and versatile. It works very efficiently. It is composed of a protein
component called Cas9 that is represented on this slide as scissors. This protein, Cas9,
has the ability to recognize site-specifically a certain sequence on the DNA, a certain sequence
of interest, as the ability to cleave the DNA. This Cas9 protein is programmed by the help of
RNA component that allows to bring Cas9 to the site of interest. This is a technology that has
largely been adopted by the scientific community and has become very popular since the start of
its discovery in 2012. I would like to explain to you why this technology is transformative.
The field of genetics started in the 19th century up to the mid-20th century,
whereby rules for fundamental genetics were established with the DNA that was isolated,
the DNA that was shown to be the carrier of information, and then the genetic code that
was deciphered over the last years in the 60s. The last 50 years have witnessed the large
development of a number of technologies, actually all originating from research done on bacteria
and viruses. This started in the 70s with different types of enzymes and technologies
that would allow to recombine DNA, to clone DNA, to sequence DNA, amplify DNA, target genes and
their expression. The zinc finger and talon nucleases that were discovered over the last
20 years allow precise genetics, the same as what CRISPR-Cas9 does, except that CRISPR-Cas9
brings a level of programmability and a level of simplicity and versatility that is quite unique.
We are all very happy because we can now study cells and organisms that were difficult to study
prior to CRISPR-Cas9. The research on CRISPR-Cas9 originates, in my lab, from our interest in
understanding how streptococcus pyogenes causes diseases in humans. Streptococcus pyogenes
belongs to the class of gram-positive bacteria such as Listeria and Staphylococci. These bacteria
have been the main focus of my research during my career. I have always been interested in
understanding how bacteria interact with their environment, so in principle the human host,
how they can cause diseases, how they can adapt to their environment, survive in the human host,
and also to a certain extent how the human host can defend itself against bacterial infections.
The focus has always been on regulatory mechanisms that use proteins and small
RNAs. The family of small RNAs is an interesting family of regulatory elements,
which we started to work on at the beginning of 2000, so about 20 years ago. This research
was always mixed with a need to develop gene technologies along the way, just to be able to
study better those mechanisms in bacteria, specifically in the context of their interactions
with the human host. During my years as a PhD and postdoc, I was certainly handicapped by the
non-possibility to perform genetics in human cells, which is really the host for these strict
human pathogens. So I have developed genetic tools in bacteria. I have also worked on transgenic
mice, coming back to understanding the interaction between bacteria and the human host and
understanding as well that there was a lack of tools that would allow to perform precise genetics
in human cells, for example. This is what CRISPR-Cas9 can do.
The field of small RNAs has largely evolved over the last 30 years. This was a discovery that
RNA molecules, in addition to being messenger RNA or transfer RNA or ribosomal RNAs and being
involved in the transcription of the DNA and translation into proteins, that RNAs are also
regulatory functions and would be able to interact with messenger RNA molecules and also with
proteins and regulate the expression of genes. What was not identified about 10-15 years ago,
these were small RNAs that would have the ability to change gene expression by interacting directly
with DNA. We were working on some small regulatory RNAs. We published some data showing that some of
these small regulatory RNAs had the ability to change the expression of virulence factors in
bacteria, so contributed a lot to the adaptation of bacteria to their environment. We decided about
15 years ago to start a search for additional regulatory RNAs. We found a number of those RNAs
and we particularly picked an RNA that is known as tracer RNA because this RNA was very well
expressed in bacterial cells. You can see the gel that is a northern blot analysis showing the
expression of these RNAs as different forms in streptococcus pyogenes. We had found a target
for this small regulatory RNA, so initially we thought that it would have a role in regulating
the expression of a virulence factor. We had difficulties to make sense of this interaction,
but what was clear is that at least this RNA was encoded in the vicinity of a gene that was
annotated to be a gene encoding a protein that was CRISPR related, a protein containing
two nucleus domains, so a CRISPR protein that would have the ability to cleave nucleic acids.
This was a start of nonetheless continuing our research on tracer RNA, but also working on
CRISPR. CRISPR is to be seen and considered as part of different systems which bacteria and
archaea have evolved over millions of years. Bacteria and archaea can be infected by viruses
as we can be infected by viruses and bacteria and have evolved diverse immune systems that allow
them to cope with the invasion of genetic elements such as viral elements, but also other
elements such as plasmids and transposons. This really actually is important and to be seen in
the context of of the fitness of the bacteria with their environment and the evolution of
the microorganisms. So here on this slide you can see a phage that is infecting a bacterial cell
with the genomic component of the phage that is injected into the bacterial cell,
the genomes of the virus that can replicate, and then you have the formation of viral particles
that can lyse bacterial cells and propagate to lyse further bacterial cells. So here we deal
with phages, viruses that can kill bacterial cells and surely the need for bacteria to have
evolved systems that allow them to defend themselves against death. So what is interesting
is that some of these immune systems have been developed over the years as genetic tools,
so for example restriction enzymes are originally actually different systems existing in bacteria.
CRISPR is unique in the sense that it is an adaptive immune system, there is a first step
of recognition that leads to the immunity, and it is composed of protein components,
the cas proteins, and RNA components, the CRISPR RNA. So I do not have the time to go very deeply
into the history of the CRISPR-Cas research, however I would like to mention that this has
involved a number of scientists who have really performed a pioneer work on CRISPR-Cas. I have
read all the publications on CRISPR-Cas when we started to work on the CRISPR-Cas9 system in my
lab, and this is really by reading all those articles that it allowed me to really understand
what would be different of the CRISPR-Cas9 system compared to other CRISPR-Cas systems that were
studied by my colleagues. But in brief, the CRISPR components are such that the first
identification were the repeats of the CRISPR array, so the CRISPR array is formed by very
short sequences that are identical to one another that forms repeats and that are interspaced by
sequences that have as origin mobile genetic elements. This CRISPR array was shown to be able
to be transcribed into RNA molecules of different sizes, so probably maturation events taking place
to activate those CRISPR RNA molecules. In the vicinity of the CRISPR array, you have the
CRISPR-associated genes that encode the CRISPR-associated proteins, and very fast as well,
there was the observation that these CRISPR-associated proteins contain domains that
are homologous to domains contained in proteins that have the ability to target DNA, target RNA,
and also cleave DNA and cleave RNA. So all together, the idea was that these CRISPR-Cas
systems would be obviously adaptive immune systems in bacteria and archaea that was shown
experimentally later on in Streptococcus thermophilus, but that also those systems
were identified as prokaryotic RNA interferon systems by analogy to RNA interferon systems.
So when we started the research, the dogma was that there would be a complex of CRISPR-associated
proteins that will be formed and that will associate to the CRISPR RNA to act as a machinery
that would allow to target the DNA or the RNA. So the way it works is as follows.
The system is adaptive in the sense that the bacteria have first recognized the virus and will
have the ability to memorize the infection by the virus, and this is the way it is done. So the virus
will inject its DNA into the bacterial cell. The CRISPR-Cas system will be able to recognize
the invading DNA, cleave a certain sequence of the invading DNA and insert this sequence into
the CRISPR array, and this is working as a kind of memorization of the virus. Then you will have
expression at the RNA level of these memorized elements of viral infections. The CRISPR RNAs
will associate with a complex of CRISPR-associated proteins, and those RNAs allowing to guide the
CRISPR-associated proteins to the invading DNA of the virus upon a second infection.
And this is the way it works, and there will be recognition of the virus and one
protein of the CRISPR-Cas system will ultimately cleave the invading DNA,
and the DNA cannot replicate, and this is a dead end for the virus. So this is globally how it works.
In streptococcus pyogenes, we were lucky enough to have on the genome of streptococcus pyogenes
genes that were belonging to a certain type of CRISPR-Cas system that was not studied yet,
at least at the molecular level. What the groups of Horvath, Barangu, and Wano had shown is that
the CRISPR-Cas9 system was really in streptococcus thermophilus, involving one
CRISPR-associated protein, Cas9, that will be involved in the recognition of the virus upon
infection, but the molecular mechanism was not described, and this is what we
started in our lab. So we decided to look at the question whether tracer RNA would actually
have a regulatory role on the CRISPR-Cas system, and this is what we found. What we found is that
tracer RNA contains an anti-repeat sequence that allows it to base pair with the repeats of the
CRISPR RNAs, and this duplex of RNA is actually stabilized by the protein Cas9. Then, following
this, it's going to be maturated by enzymes in the bacteria, specifically the RNAs3,
and further RNAses that will lead to the mature form of the duplex of RNAs still bound to the
protein Cas9. Then this complex of Cas9, guided by the duplex of RNA, will be able to recognize
specifically the DNA and cleave the DNA using two nucleus domains and cleave the DNA in a
sequence-specific manner. So this is what we have shown, seeing right away that the system from
was working very efficiently with cleavages that were as we were expecting.
And now with regard to the programmability of the system, the idea was to simplify this duplex of
RNA and fuse those two RNAs to have a single guide RNA that will be the programmable element
of the CRISPR-Cas9 system, so bringing simplicity for the design of the technology.
One thing that is important to mention is that the mechanism is very sophisticated in the sense
that the ability to use two nucleus domains to cleave the DNA and this programmability allowed
to develop the Cas9 technology further into a technology that can really perform multiple
modifications on the genome. So it can correct mutations, introduce new mutations on the DNA,
it can allow to delete genes, delete certain sequences of DNA, add new sequences of DNA at
the site of interest, replace genes by other genes. And over the last eight years a number
of scientists and developers have really put forward the technology to really have the technology
evolving in multiple versions that allow to do some multiplexing and that really allow to perform
precise genetics in an unprecedented manner. Very fast actually, scientists adopted this
technology and showed in a very very short amount of time that the technology was efficient
to act on the DNA and modify genes and their expression in a variety of cells including
human cells, in organoids, in model organisms such as mice, fish, fly and also plants. So a very
transformative technology. I do not have for sure the time to explain you all the details of the
science behind the CRISPR-Cas9 system but CRISPR-Cas is a largely evolving system,
all the CRISPR-Cas systems including CRISPR-Cas9. And this is early on the diversity of this system
that we understood what would be conserved and what would be the basis of the mechanism. So we
this Cas9 protein guided by a duplex of RNA and that could be among all the different CRISPR-Cas
systems existing that will be the system minimal enough to harness as a powerful gene technology.
And this is quite amazing how the systems have evolved. They have evolved surely in multiple
other systems than the CRISPR-Cas9 system. Now we have two classes identified and within each
of the class multiple systems and subsystems. So since CRISPR-Cas9 other minimal systems have been
identified, further developed also as CRISPR-Cas technology. So enlarging the CRISPR-Cas toolbox.
You have large applications for this genome editing technology. So for sure to understand
better mechanisms of life. So it's very useful for fundamental research to unravel novel molecules,
novel pathways, to be able to really work with the cells and organisms that are of interest for
clinical purposes. The technology has been also very well developed with regard to
the applications in understanding better the mechanisms of life sciences in model organisms
such as mice, drosophila and fish. It has also been a game changer for allowing precise genetics
in plants and it has large applications in medicine either directly or indirectly
by allowing to develop better models of diseases and also by allowing to develop the CRISPR-Cas9
technology as a direct tool for really to work as a gene medicine and use the technology directly
to treat certain types of diseases such as human genetic disorders or certain cancers
by combining the CRISPR-Cas9 technology with immunotherapy. It's also very transformative
in the field of plant biology with the production of plant crops, surely with ethical considerations
that have to be taken into account. What next? So surely the CRISPR biologists continue to work
on this field, continue to identify novel CRISPR-Cas9 systems thanks to the sequencing
of novel genomes of bacterial species and archaea species. Recently novel defense systems in bacteria
and archaea have been identified and this will continue so we can expect from research on microbes
to have further genetic technologies to be identified in the future. It is an exciting
research for young scientists because now the young scientists have a really powerful tool to
study their cells and organisms of interest and do genetics in a way that was not possible
20-25 years ago. What is very interesting with the timeline of all those technologies is that
the impact of CRISPR-Cas9 makes even more sense with regard to all the technologies that have
developed over the last 15-20 years such as high-throughput technologies to sequence
genomes, high-throughput technologies for screening, all the technologies of
imaging and all the technologies that have largely evolved delivering technologies to deliver
gene technologies such as CRISPR-Cas9 in cells and organisms and also new technologies that allow
to culture cells and organisms that were not possible to culture 15-20 years ago. This makes
global sense and that's why I think it's really an exciting time to be able to study the evolution
and the diversity of the world. Another message that I would like to provide as well is that,
as a matter of fact, CRISPR-Cas9 originates from research done on bacteria and viruses
and we do know nowadays how important it is to really maintain the research in macrobiology,
to maintain the expertise and to study more bacteria and viruses, not only because
they can cause diseases and we need to find new treatments for those infectious diseases,
but also because the last 50 years have shown to which extent bacteria and viruses are really
a valuable source for the development of novel biotechnologies. I would like to
thank surely the people who have done the work. This work would not have been possible without
young scientists being extremely committed and extremely enthusiastic. The work from my
side started in Vienna at the Max Bird Labs at the University of Vienna. The main part was done
when I was a principal investigator at the Laboratory for Molecular Infection Medicine,
Sweden, at Umeå University. I would like to thank a number of people, but I would like to mention
Maria Eckert, who was a postdoc in my lab in Vienna identifying tracer RNA, Christoph
Chilinski and Elisa Delcheva, who have been key students driving the project forward. I would like
to thank my collaborators Eugenie Konin, Kira Makarova, Cynthia Sharma, Jörg Vogel, Martin
Ineck and surely Jennifer Donner, my co-laureate. This was a great time as this research developed
within five years of time, at least from my lab, and I really enjoyed this exciting time working
with wonderful collaborators. I would like also to take the opportunity to thank all my former
and lab members who have worked with me the last 18 years in Austria, Sweden and Germany.
It has always been a pleasure to work with young scientists and this is also the reason why I like
to do science. And last but not least, I would like to thank my family, my friends, Rodger Novak,
and all my colleagues who have supported my work and who have helped me during my career.
And I would like to thank you for your attention.
